Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Oral PIPE-307 As an Adjunctive Treatment in Subjects with Relapsing-Remitting Multiple Sclerosis

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Oral PIPE-307 As an Adjunctive Treatment in Subjects with Relapsing-Remitting Multiple Sclerosis

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PIPE-307 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms VISTA
  • Sponsors Contineum Therapeutics

Most Recent Events

  • 06 Mar 2025 According to Contineum Therapeutics media release, the company expect topline data from trial in the second half of 2025.
  • 07 Jan 2025 Status changed from recruiting to active, no longer recruiting.
  • 06 Nov 2024 According to Contineum Therapeutics media release, As of September 30, 2024, company had achieved two-thirds enrollment in its VISTA clinical trial and now company expects the VISTA trial to be fully enrolled in the first half of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top